# Skechers U.S.A. Inc. (SKX) — Financial Analysis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-27  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/SKX/thesis · /stocks/SKX/memo

## Financial Snapshot

---
source: coverage-next-full
ticker: SKX
company: Skechers U.S.A., Inc.
step: 04
title: Financial Snapshot & Adversarial Research Sweep
created: 2026-05-27
---

### Step 04 — Financial Snapshot: SKX (Skechers U.S.A., Inc.)

#### 1. Statement-Quality Adjustments

##### Non-Controlling Interest (NCI) Complexity

Skechers consolidates several joint ventures, most notably in China, where minority partners hold significant stakes. In FY2024, NCI attributed $90.1M of net income to JV partners (vs. $104.1M in FY2023). This creates a gap between consolidated net income ($729.6M) and net income attributable to SKX ($639.5M) [S1].

**Adjustment required:** Investors should focus on net income attributable to SKX ($639.5M) and EPS ($4.16) rather than consolidated figures. EBITDA and operating income are not distorted by NCI.

##### Stock-Based Compensation

SBC has grown from $57.3M (FY2022) to $83.4M (FY2024), representing 0.93% of revenue. While this is below peer median, the absolute dollar amount is meaningful in the context of ~$640M net income. SBC-adjusted FCF is approximately $270.6M (CFO $687.4M - CapEx $416.8M), and true economic earnings are below reported GAAP EPS due to SBC dilution [S2].

##### Operating Lease Obligations

Skechers operates ~5,000 stores globally under operating leases. While these appear on-balance-sheet under ASC 842, the total lease liability represents a significant off-income-statement obligation. CapEx ($416.8M in FY2024) includes fit-out of new retail locations and DC expansion — this is recurring infrastructure investment, not maintenance CapEx.

##### GAAP to Adjusted EBITDA Bridge (FY2024 estimate)

| Line Item | Amount |
|-----------|--------|
| Operating Income (EBIT) | $904.3M |
| + D&A (estimated ~$300-330M based on asset base) | ~$315M |
| **EBITDA (estimated)** | **~$1,219M** |
| + SBC | $83.4M |
| **Adjusted EBITDA (estimated)** | **~$1,302M** |

Deal EV/EBITDA at $9.4B acquisition: ~7.7x trailing adj. EBITDA — consistent with a quality consumer brand with moderate growth [S3].

#### 2. Income Statement Quality Assessment

**Revenue recognition:** Footwear is a goods-based business; revenue recognized upon transfer of control. No complex multi-element arrangements. Revenue quality: HIGH [S1].

**Gross margin trajectory:** FY2022 47.2% → FY2024 53.2% (+600 bps). The expansion is real and driven by: (1) freight normalization ($3.8B COGS declined to $3.85B from $3.93B despite revenue growth), (2) DTC mix, (3) lower input costs. Not a one-time benefit [S1].

**Operating leverage:** Revenue +12.1% YoY; operating income +15.2%. Positive leverage is real. G&A grew 13.8% vs revenue +12.1% — slightly negative jaws — driven by store expansion costs. Net, operating margin expanded +30 bps [S1].

**Tax rate:** Effective rate 16.9% (FY2024) vs 18.8% (FY2023) due to favorable geographic earnings mix. Management guided 22-23% for FY2025 due to OECD Pillar Two — this is a real headwind to reported EPS [S1].

#### 3. Cash Flow Quality

| Metric | FY2022 | FY2023 | FY2024 |
|--------|--------|--------|--------|
| CFO | $238.3M | $1,231.2M | $687.4M |
| CapEx | $359.0M | $323.7M | $416.8M |
| FCF | ($120.7M) | $907.5M | $270.6M |
| Buybacks | $74.2M | $160.1M | $330.1M |
| Net Income (SKX) | $373.0M | $545.8M | $639.5M |

**FY2023 CFO spike explanation:** Inventory normalized dramatically in FY2023 after elevated FY2022 inventory build. Working capital release drove one-time CFO uplift. FY2024's $687.4M CFO is more representative of normalized earnings power [S2].

**CapEx elevation:** Rising from $324M (FY2023) to $417M (FY2024) reflects accelerating DC investment (new U.S. distribution center, China DC expansion) and retail footprint growth. This is strategic investment, not a quality concern, but free cash flow conversion will remain compressed.

#### 4. Balance Sheet Quality

| Item | FY2024 | FY2023 | Δ |
|------|--------|--------|---|
| Cash | $1,116.5M | $1,189.9M | ($73.4M) |
| A/R | $990.6M | $860.3M | +$130.3M |
| Inventory | $1,919.4M | $1,525.4M | +$394.0M |
| LT Debt | $421.6M | $289.5M | +$132.1M |
| Total Equity | $4,277.3M | $4,019.3M | +$258.0M |

**Inventory build:** $1.53B → $1.92B (+25.8%) outpaces revenue growth (+12.1%). This is worth monitoring — could reflect deliberate pre-tariff inventory build ahead of China tariff escalation, or slower-than-expected sell-through. Not a red flag at this stage but worth tracking in future quarters [S2].

**AR growth:** $860M → $991M (+15.2%) approximately in line with revenue growth (+12.1%). Days Sales Outstanding approximately stable. No collection deterioration evident [S2].

**Debt structure:** LT debt $421.6M is modest relative to EBITDA (~$1.2B). Net cash positive position (~$695M). This conservative balance sheet is what enabled 3G Capital to deploy leverage in the privatization [S3].

---

#### 5. Adversarial Research Sweep

*Examining short seller reports, investigations, regulatory actions, and litigation against Skechers.*

##### A. ShapeUps Litigation (Historical)

**Issue:** Skechers' toning shoe product line ("ShapeUps") marketed as providing fitness benefits (toning legs, buttocks). FTC and class-action plaintiffs alleged the claims were unsubstantiated.

**Resolution:** In 2012, Skechers paid $40M to settle FTC charges and consumer class-action claims. The company discontinued the ShapeUps product line. This was a material reputational and financial event but occurred over a decade ago and is not an ongoing risk [S4].

**Current relevance:** LOW. Skechers has avoided similar marketing overclaims since 2012. Comfort technology claims (Arch Fit being "podiatrist-designed") are more defensible. No repeat incidents noted.

##### B. Employment and Labor Litigation

**Issue:** Skechers has faced various employment-related class actions over the years (wage and hour disputes, primarily in California). These are endemic to any large retailer with California operations.

**Status:** No material undisclosed litigation identified. FY2024 10-K notes $22.3M increase in legal costs YoY as a G&A driver — but this appears to reflect broader portfolio of routine commercial disputes, not a single material event [S1].

##### C. IP/Trademark Disputes

**Issue:** As a global footwear brand with operations in 170+ countries, Skechers regularly encounters trademark infringement (both as plaintiff and defendant).

**Notable:** Nike sued Skechers in 2024 over trade dress infringement related to running shoe designs. Cases of this type are common in the industry (Nike sues frequently). Materiality appears low; no significant judgment disclosed [S4].

##### D. Greenberg Family Governance / Related Party Transactions

**Issue:** Dual-class voting structure (Class B = 10 votes) concentrates control with Robert Greenberg. Proxy statements have disclosed related-party transactions including the company's former use of a Greenberg-family-connected property (since resolved).

**Assessment:** The governance structure created a long-standing governance discount in the stock. ISS and Glass Lewis have historically recommended against board members due to dual-class structure. The 3G Capital acquisition at $63/share effectively resolved this discount — minority shareholders received full deal value [S5].

##### E. Supply Chain/Labor Standards

**Issue:** Like all major footwear brands manufacturing in Asia, Skechers has received occasional NGO scrutiny over factory labor conditions.

**Assessment:** No material regulatory action or significant labor violation disclosed. Skechers maintains quality control offices in China and Vietnam specifically for factory oversight. This is standard industry practice, not a differentiated risk [S1].

##### F. China JV Opacity

**Issue:** Skechers' China operations are conducted through a consolidated joint venture. The JV partner identities and specific economics are not fully disclosed.

**Assessment:** NCI is disclosed (FY2024: $90.1M), and the China revenue ($1.22B) and PP&E ($303.6M) are disclosed. However, the JV structure creates opacity around profitability by channel and strategic governance. This is a genuine analytical blind spot but not evidence of impropriety [S1].

##### G. Short Seller History

No prominent short seller reports identified targeting SKX accounting or business model integrity. The stock has had periods of high short interest related to tariff concerns and competitive fears, but no targeted adversarial research campaigns found.

**Overall Adversarial Assessment:** No material accounting irregularities, ongoing regulatory investigations, or credible fraud allegations identified. Primary risks are competitive (market share), operational (tariff), and governance (dual-class) — all well-disclosed and widely understood by investors.

#### 6. Source Index

| Code | Source | URL/File |
|------|--------|----------|
| [S1] | SKX FY2024 10-K | sec.gov/Archives/edgar/data/1065837/000095017025030016/skx-20241231.htm |
| [S2] | XBRL balance sheet and cash flow data | xbrl/xbrl_summary.md |
| [S3] | 3G Capital acquisition | bloomberg.com, about.skechers.com |
| [S4] | ShapeUps FTC settlement and Nike litigation | Public FTC records; news reporting |
| [S5] | Governance proxy data | proxy/governance_and_compensation.md |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/SKX/fundamental

## Navigation

- Overview: /stocks/SKX
- Financials (this page): /stocks/SKX/financials
- Thesis: /stocks/SKX/thesis
- Investment Memo: /stocks/SKX/memo
- Coverage universe: /stocks